Read article - An article reporting that research on a new antibody cancer drug spearheaded by Randolph Noellem, professor of microbiology and immunology, has begun human clinical trials. The drug, CI-8993, is an anti-VISTA (V-domain Ig Suppressor of T-cell Activation) antibody that is designed to target a molecule that keeps the immune system quiet against cancer.
Upcoming Events
- Pediatric Grand Rounds April 24, 2024
- Preventing Overdiagnosis Webinar: Why cancer is our most feared disease. April 25, 2024
- Discovery Science Seminar Series April 29, 2024
- Microbiology & Immunology Seminar Series - Akhenaton-Andrew Dhafir Jones III, Ph.D. April 29, 2024
- Psychiatry Grand Rounds April 30, 2024
- Pediatric Grand Rounds May 1, 2024
- Thesis Defense (Kaesi Morelli) May 1, 2024
- Spring DEIB Series "Following the Arc towards Justice: An Editor's Perspective" May 1, 2024
- Spring DEIB Series "Following the Arc towards Justice: An Editor's Perspective" May 2, 2024
- M&I Thesis Defense - Leena Abdullah May 2, 2024
- Microbiology and Immunology Graduate Seminar May 2, 2024
- Dept. of Surgery Grand Rounds May 3, 2024